Kavya Prasad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kavya Prasad has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Erik F. J. de Vries
Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
3 shared publications - Aren van Waarde
University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Groningen, The Netherlands
2 shared publications - Daniel Aaron Vazquez-Matias
Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2 shared publications - Rodrigo Moraga-Amaro
Laboratorio de Neurobiología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad Andres Bello, Santiago 8370146, Chile
2 shared publications - Rudi A. J. O. Dierckx
Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
2 shared publications Antoon T. M. Willemsen
Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, P.O. Box 30001, 9713 GZ Groningen, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 5 February 2024
- Published by Elsevier in Neuropharmacology
- Vol. 247, 109862
Effects of the adenosine A2A receptor antagonist KW6002 on the dopaminergic system, motor performance, and neuroinflammation in a rat model of Parkinson's disease
- 5 February 2024
- Published by Elsevier in Neuropharmacology
- Vol. 247, 109862
Open AccessEffects of the adenosine A2A receptor antagonist KW6002 on the dopaminergic system, motor performance, and neuroinflammation in a rat model of Parkinson's disease
- Open Access
- 18 July 2022
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 19 (8) , 2992-3001
Impact of an Adenosine A2A Receptor Agonist and Antagonist on Binding of the Dopamine D2 Receptor Ligand [11C]raclopride in the Rodent Striatum
Adenosine A(2A) and dopamine D-2 receptors in the basal ganglia form heterotetrameric structures that are involved in the regulation of motor activity and neuropsychiatric functions. The present study examines the A(2A) receptor-mediated modulation of D-2 receptor binding in vivo using positron emission tomography (PET) with the D-2 antagonist tracer [C-11]raclopride. Healthy male Wistar rats (n = 8) were scanned (60 min dynamic scan) with [C-2A]raclopride at baseline and 7 days later following an acute administration of the A2A agonist CGS21680 (1 mg/kg), using a MicroPET Focus-220 camera. Nondisplaceable binding potential (BPND) values were calculated using a simplified reference tissue model (SRTM), with cerebellum as the reference tissue. SRTM analysis did not show any significant changes in [11C]raclopride BPND (p = 0.102) in striatum after CGS21680 administration compared to the baseline. As CGS21680 strongly affects hemodynamics, we also used arterial blood sampling and a metabolite-corrected plasma input function for compartment modeling using the reversible two-tissue compartment model (2TCM) to obtain the BPND from the k3/k4 ratio and from the striatum/ cerebellum volume of distribution ratio (DVR) in a second group of animals. These rats underwent dynamic [11C]raclopride scans after pretreatment with a vehicle (n = 5), a single dose of CGS21680 (1 mg/kg, n = 5), or a single dose of the A2A antagonist KW6002 (1 mg/kg, n = 5). The parent fraction in plasma was significantly higher in the CGS21680-treated group (p = 0.0001) compared to the vehicle-treated group. GCS21680 administration significantly reduced the striatal k3/k4 ratio (p < 0.01), but k3 and k4 estimates may be less reliable. The BPND (DVR-1) decreased from 1.963 & PLUSMN; 0.27 in the vehicle-treated group to 1.53 & PLUSMN; 0.55 (p = 0.080) or 1.961 & PLUSMN; 0.11 (p = 0.993) after the administration of CGS21680 or KW6002, respectively. Our study suggests that the A2A agonist CGS21680, but not the antagonist KW6002, may reduce the D2 receptor availability in the striatum.
- 18 July 2022
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 19 (8) , 2992-3001
Open AccessImpact of an Adenosine A2A Receptor Agonist and Antagonist on Binding of the Dopamine D2 Receptor Ligand [11C]raclopride in the Rodent Striatum
Adenosine A(2A) and dopamine D-2 receptors in the basal ganglia form heterotetrameric structures that are involved in the regulation of motor activity and neuropsychiatric functions. The present study examines the A(2A) receptor-mediated modulation of D-2 receptor binding in vivo using positron emission tomography (PET) with the D-2 antagonist tracer [C-11]raclopride. Healthy male Wistar rats (n = 8) were scanned (60 min dynamic scan) with [C-2A]raclopride at baseline and 7 days later following an acute administration of the A2A agonist CGS21680 (1 mg/kg), using a MicroPET Focus-220 camera. Nondisplaceable binding potential (BPND) values were calculated using a simplified reference tissue model (SRTM), with cerebellum as the reference tissue. SRTM analysis did not show any significant changes in [11C]raclopride BPND (p = 0.102) in striatum after CGS21680 administration compared to the baseline. As CGS21680 strongly affects hemodynamics, we also used arterial blood sampling and a metabolite-corrected plasma input function for compartment modeling using the reversible two-tissue compartment model (2TCM) to obtain the BPND from the k3/k4 ratio and from the striatum/ cerebellum volume of distribution ratio (DVR) in a second group of animals. These rats underwent dynamic [11C]raclopride scans after pretreatment with a vehicle (n = 5), a single dose of CGS21680 (1 mg/kg, n = 5), or a single dose of the A2A antagonist KW6002 (1 mg/kg, n = 5). The parent fraction in plasma was significantly higher in the CGS21680-treated group (p = 0.0001) compared to the vehicle-treated group. GCS21680 administration significantly reduced the striatal k3/k4 ratio (p < 0.01), but k3 and k4 estimates may be less reliable. The BPND (DVR-1) decreased from 1.963 & PLUSMN; 0.27 in the vehicle-treated group to 1.53 & PLUSMN; 0.55 (p = 0.080) or 1.961 & PLUSMN; 0.11 (p = 0.993) after the administration of CGS21680 or KW6002, respectively. Our study suggests that the A2A agonist CGS21680, but not the antagonist KW6002, may reduce the D2 receptor availability in the striatum.
- 1 December 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 53, S182-S183
P.0251 Influence of the a2a antagonist kw6002 on dopaminergic system, motor functioning and neuroinflammation in a rodent model of parkinson's disease
- 1 December 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 53, S182-S183
P.0251 Influence of the a2a antagonist kw6002 on dopaminergic system, motor functioning and neuroinflammation in a rodent model of parkinson's disease